Talaris Therapeutics

Harnessing the power of immune tolerance.

[Talaris Therapeutics @TalarisTx]

#AutoimmuneDiseaseAwarenessMonth is an opportunity to honor the millions of people worldwide living with autoimmune conditions, including #scleroderma. We’re proud to be part of the research community working to deliver better treatments for autoimmune diseases.

[Talaris Therapeutics @TalarisTx]

Today on #RareDiseaseDay, the National @scleroderma Foundation will be among the many groups worldwide calling attention to rare diseases. Follow along their page as they highlight the faces of #scleroderma every hour today.

@rarediseaseday

[Talaris Therapeutics @TalarisTx]

We’re in Orlando for #Tandem23 hosted by @ASTCT and @CIBMTR and looking forward to sharing poster presentations on the design of our 3 #celltherapy clinical trials. Stop by our booth to learn more: https://t.co/zSOElVsRwR

[Talaris Therapeutics @TalarisTx]

Today we celebrate #NationalDonorDay and support @DonateLife’s commitment to spreading awareness and education about #organdonation.

To change the future of someone in great need, consider giving the gift of life. Register to be an organ donor at https://t.co/B7PhF1sOPU

[Talaris Therapeutics @TalarisTx]

#TeamTalaris is on a mission to harness the power of immune tolerance to improve people’s lives. Our most important asset in that work is our people, people like Tyrell. Learn more about our team: https://t.co/QDd9yV0rpp

#Louisville #Houston #Boston

[Talaris Therapeutics @TalarisTx]

#February11, or International Day of Women and Girls in Science, is a time to honor all the women on #TeamTalaris. Learn more about what motivates our very own Rubina Pal and Hayley Squires who have chosen a career in life sciences.

#WomenInScience #STEM #IDWGIS

[Talaris Therapeutics @TalarisTx]

Today we’re at the 2023 Hypertension & Kidney Transplantation Update for the Clinician hosted by @MayoClinicEd. This three-day symposium will allow healthcare professionals to discuss clinical nephrology advancements.

For more: https://t.co/WwgxKT01da

[Talaris Therapeutics @TalarisTx]

Talaris is pleased to share that our FREEDOM-1 trial is now enrolling at #UTSouthwestern Medical Center (@UTSWNews). For more information on FREEDOM-1, our phase 3 trial for living donor #kidneytransplant patients, visit: https://t.co/wnyWZzJFMk

#UTSW #DallasCounty

[Talaris Therapeutics @TalarisTx]

Check out our latest video featuring patient advocate and transplant recipient Kevin Fowler (@gratefull080504), about the importance of embracing a healthy lifestyle after a #kidneytransplant: https://t.co/jpzDXbQHJt

[Talaris Therapeutics @TalarisTx]

Check out @PKDFoundation’s helpful tips for #kidneypatients on how to prepare for a #kidneytransplant.

To learn more on how to join their united fight to #endPKD visit: https://t.co/K9CWu1OQ1g

[PKD Foundation @PKDFoundation]

How should you prepare for a kidney transplant? New Orleans nephrologists Zohreh Soltani, M.D. and Siddhartha Bajracharya, M.D. share their recommendations on the blog today.

https://t.co/c9w5NrJeUM

[Talaris Therapeutics @TalarisTx]

The #FREEDOM1 trial is enrolling individuals seeking a #livingdonor #kidneytransplant. Curious if you or a loved one might qualify? Find out by taking a short quiz: https://t.co/wnyWZzJFMk

#kidneys #organdonation #antirejection #transplantlife

[Talaris Therapeutics @TalarisTx]

Talaris is at @NKFServingOhio’s 2023 Kidney & Transplant Symposium and will spend the day with renal professionals discussing the treatment of #kidneydisease, #transplantation, and #organdonation.

Learn how to support those affected by kidney disease: https://t.co/De6GxUB44q

[Talaris Therapeutics @TalarisTx]

#ICYMI – Talaris Chief Human Resource Officer Andrew Farnsworth recently shared his insights on how organizations can be successful in establishing core values.

Read his reflections here: https://t.co/G7TnvbptPL

[Talaris Therapeutics @TalarisTx]

Our #FREEDOM2 clinical trial is evaluating whether FCR001, our investigational #celltherapy, can induce #immune tolerance in recent #livingdonor #kidneytransplant recipients without depending on #antirejection drugs.

Visit our website for more info: https://t.co/mxqFMktQlB

[Talaris Therapeutics @TalarisTx]

Talaris Patient Advisory Board member Gisela Delgado recently shared her experience being on #immunosuppressive medicines after her #kidneytransplant as a panelist at the @ttsorg 2022 Congress.

See an excerpt of her talk: https://t.co/CDuSE8DyaK

[Talaris Therapeutics @TalarisTx]

Empowered.
Compassionate.
Energized.
Revolutionary.

These are the four core values #TeamTalaris embodies every day as we continue harnessing the power of immune tolerance to improve people’s lives.

Learn more about Talaris’ culture at: https://t.co/CgHlKyZxvr

[Talaris Therapeutics @TalarisTx]

Talaris’ #FREEDOM1 study is evaluating the potential of our investigational #stemcell therapy, FCR001, to free #livingdonor #kidneytransplant recipients from chronic immunosuppression.

See if you qualify: https://t.co/D3tjXKSFHK

[Talaris Therapeutics @TalarisTx]

Today we’re attending #ASTSWinter hosted by @ASTSChimera. We look forward to connecting with #transplant professionals who share our dedication to improving patients’ lives. Visit our booth to learn more about Talaris’ solid #organtransplant clinical trial.

[Talaris Therapeutics @TalarisTx]

A new paper authored by our Chief Medical Officer Nancy Krieger and leading #scleroderma experts Dr. Dinesh Khanna (@sclerodermaUM) & Dr. Keith Sullivan reviews new cell therapies in development for treating #autoimmune diseases. https://t.co/rZJ3Tc0XwP

[Talaris Therapeutics @TalarisTx]

#DYK: Though kidneys are the most-transplanted organ, the waitlist for a kidney grows longer each year. Learn more about kidney health from @nkf: https://t.co/57sgC1NK9p